Last update 29 Aug 2025

Fujian Akeylink Biotechnology Co., Ltd

Subsidiary Company|2021|Fujian Sheng, China

Overview

Basic Info

Introduction
Fujian Akeylink Biotechnology Co., Ltd. operates as a subsidiary under the majority ownership of Fujian Guangshengtang Pharmaceutical Co., Ltd. The company's primary focus lies in the development and marketing of the oral small molecule 3CL protease inhibitor Taierteve GST-HG171 tablets, aimed at combating COVID-19.

Tags

Respiratory Diseases
Infectious Diseases
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Infectious Diseases3
Top 5 Drug TypeCount
Small molecule drug3
Top 5 TargetCount
HIV-1 protease x SARS-CoV-2 3CLpro1
SARS-CoV-2 3CLpro(SARS-CoV-2-3C-like-proteinase)1

Related

3
Drugs associated with Fujian Akeylink Biotechnology Co., Ltd
Atilotrelvir/Ritonavir
Target
HIV-1 protease x SARS-CoV-2 3CLpro
Mechanism
HIV-1 protease inhibitors [+1]
Active Org.
Fujian Akeylink Biotechnology Co., Ltd
Originator Org.
Fujian Akeylink Biotechnology Co., Ltd
Active Indication
COVID-19
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
China
First Approval Date23 Nov 2023
Atilotrelvir
Target
SARS-CoV-2 3CLpro
Mechanism
SARS-CoV-2 3CLpro inhibitors
Active Org.
Fujian Akeylink Biotechnology Co., Ltd
Originator Org.
Fujian Akeylink Biotechnology Co., Ltd
Active Indication
COVID-19
Inactive Indication-
Drug Highest PhasePhase 2/3
First Approval Ctry. / Loc.-
First Approval Date-
GST-HG181
Target-
Mechanism-
Active Org.
Fujian Akeylink Biotechnology Co., Ltd
Originator Org.
Fujian Akeylink Biotechnology Co., Ltd
Active Indication
COVID-19
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
12
Clinical Trials associated with Fujian Akeylink Biotechnology Co., Ltd
NCT07090759
/ RecruitingPhase 3
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Trial of GST-HG141（Neracorvir）for Combination Therapy (add-on) in Patients With Inadequate Response to Antiviral Drugs in Chronic Hepatitis B (CHB)
NCT06263959
/ RecruitingPhase 2
A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 Tablets in Patients With Chronic Hepatitis B
NCT06087055
/ CompletedPhase 1
An Open Labe Study to Evaluate the Drug-Drug Interaction of Itraconazole With GST-HG171/Ritonavir in Healthy Adult Chinese Participants
100 Clinical Results associated with Fujian Akeylink Biotechnology Co., Ltd
Login to view more data
0 Patents (Medical) associated with Fujian Akeylink Biotechnology Co., Ltd
Login to view more data
100 Deals associated with Fujian Akeylink Biotechnology Co., Ltd
Login to view more data
100 Translational Medicine associated with Fujian Akeylink Biotechnology Co., Ltd
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 02 Sep 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
1
1
Phase 3
Approved
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Atilotrelvir/Ritonavir
 ( HIV-1 protease x SARS-CoV-2 3CLpro )		COVID-19
More
Approved
Atilotrelvir
 ( SARS-CoV-2 3CLpro )		COVID-19
More
Phase 2/3
GST-HG181
COVID-19
More
Preclinical
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free